文献速递系统性红斑狼疮其他结缔组织病

抗磷脂抗体模式预测系统性红斑狼疮血栓风险

Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该前瞻性队列研究纳入821例系统性红斑狼疮(SLE)患者,随访75 048人月,评估七种抗磷脂抗体(aPL)组合对未来血栓风险的预测价值。结果显示狼疮抗凝物(LA)对任何、静脉和动脉血栓的预测最强,抗β2糖蛋白I IgA可增加LA阳性者的血栓风险,其他aPL组合未显著增加风险。

要点

  • LA是SLE患者任何、静脉和动脉血栓的最强预测因子。
  • 抗β2糖蛋白I IgA阳性增加任何及静脉血栓风险,且在LA阳性者中附加风险。
  • 除抗β2糖蛋白I IgA外,其他aPL组合未显著增加血栓风险。

核心结论

  • 在SLE中,LA仍是血栓的最佳预测指标,加测其他aPL未增加风险,但抗β2糖蛋白I IgA例外。

研究设计与样本

  • 前瞻性队列研究,纳入821例曾检测全部七种aPL(LA、aCL IgM/IgG/IgA、抗β2糖蛋白I IgM/IgG/IgA)的SLE患者,采用合并逻辑回归分析。

主要发现

  • 随访75 048人月,发生88例血栓事件:48例动脉、37例静脉、3例动静脉同时。
  • LA对任何血栓的年龄调整率比为3.56(95%CI 2.01, 6.30),P<0.0001;对静脉血栓为4.89(2.25, 10.64),P<0.0001;对动脉血栓为3.14(1.41, 6.97),P=0.005。
  • 抗β2糖蛋白I IgA阳性对任何血栓的率比为2.00(1.22, 3.3),P=0.0065;对静脉血栓为2.8(1.42, 5.51),P=0.0029。
  • 在LA阳性者中,抗β2糖蛋白I IgA对任何血栓的附加率比为1.73(1.04, 2.88),P=0.0362;对静脉血栓为2.27(1.13, 4.59),P=0.0218。

临床怎么用

  • 对SLE患者应检测LA以评估血栓风险,LA阳性者需关注抗β2糖蛋白I IgA。
  • 其他aPL组合的附加检测对血栓风险分层价值有限,需结合临床综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated which aPL combinations increase the risk of future thrombosis in patients with SLE. METHODS: This prospective cohort study consisted of SLE patients who had been tested for all seven aPL (LA, aCL isotypes IgM, IgG and IgA, and anti-β2-glycoprotein I isotypes IgM, IgG and IgA). Pooled logistic regression was used to assess the relationship between aPL and thrombosis. RESULTS: There were 821 SLE patients with a total of 75 048 person-months of follow-up. During the follow-up we observed 88 incident cases of thrombosis: 48 patients with arterial, 37 with venous and 3 with both arterial and venous thrombosis. In individual models, LA was the most predictive of any [age-adjusted rate ratio 3.56 (95% CI 2.01, 6.30), P < 0.0001], venous [4.89 (2.25, 10.64), P < 0.0001] and arterial [3.14 (1.41, 6.97), P = 0.005] thrombosis. Anti-β2-glycoprotein I IgA positivity was a significant risk factor for any [2.00 (1.22, 3.3), P = 0.0065] and venous [2.8 (1.42, 5.51), P = 0.0029] thrombosis. Only anti-β2-glycoprotein I IgA appeared to add significant risk to any [1.73 (1.04, 2.88), P = 0.0362] and venous [2.27 (1.13, 4.59), P = 0.0218] thrombosis among those with LA. We created an interaction model with four categories based on combinations of LA and other aPL to look at the relationships between combinations and the risk of thrombosis. In this model LA remained the best predictor of thrombosis. CONCLUSION: Our study demonstrated that in SLE, LA remained the best predictor of thrombosis and adding additional aPL did not add to the risk, with the exception of anti-β2-glycoprotein I IgA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Demir S, Li J, Magder LS, et al. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33331921. doi:10.1093/rheumatology/keaa857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。